BioSpace News Archive

Seres Therapeutics, Inc. a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update.

Indivior PLC announced its financial results for the period ending March 31, 2022.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2022, on Thursday, May 5, 2022 at 4:30 p.m. (ET).

Entera Bio Ltd announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT.

PDS Biotechnology Corporation today announced that the Company will release financial results for the first quarter of 2022 on Wednesday, May 11, 2022, before the market opens.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from first line non-small cell lung cancer patients (Part A) of the Phase II TACTI-002 trial has been selected for a prestigious Oral Presentation at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting.

ProKidney LP announced the appointment of Libbie Parker McKenzie, MD, FASN as Chief Medical Officer.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG™ delivery system, for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

Virax Biolabs Group Limited (“Virax” or the “Company”) is pleased to announce the appointment of Jason D. Davis to the role of Chief Financial Officer, effective immediately.

Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.